Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification

Na Yang, Shun Feng, Kerby Shedden, Xiaolei Xie, Yashu Liu, Charles J. Rosser, David M. Lubman, Steven Goodison

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the United States. Early clinical diagnosis of bladder cancer remains a major challenge, and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. Approach: To identify urinary proteins with potential clinical utility, we enriched and profiled the glycoprotein component of urine samples by using a dual-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry platform. Results: From a primary sample set obtained from 54 cancer patients and 46 controls, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was done on an independent set of 70 samples (35 cancer cases) by using an ELISA. Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. Summary: The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer.

Original languageEnglish (US)
Pages (from-to)3349-3359
Number of pages11
JournalClinical Cancer Research
Volume17
Issue number10
DOIs
StatePublished - May 15 2011
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Glycoproteins
Biomarkers
alpha 1-Antitrypsin
Urine
Neoplasms
Proteome
Tandem Mass Spectrometry
Affinity Chromatography
Lectins
Liquid Chromatography
Health Personnel
Cell Biology
Early Diagnosis
Patient Care
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. / Yang, Na; Feng, Shun; Shedden, Kerby; Xie, Xiaolei; Liu, Yashu; Rosser, Charles J.; Lubman, David M.; Goodison, Steven.

In: Clinical Cancer Research, Vol. 17, No. 10, 15.05.2011, p. 3349-3359.

Research output: Contribution to journalArticle

Yang, Na ; Feng, Shun ; Shedden, Kerby ; Xie, Xiaolei ; Liu, Yashu ; Rosser, Charles J. ; Lubman, David M. ; Goodison, Steven. / Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 10. pp. 3349-3359.
@article{1459f316273c428c9fe4e7719a7c6c99,
title = "Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification",
abstract = "Background: Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the United States. Early clinical diagnosis of bladder cancer remains a major challenge, and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. Approach: To identify urinary proteins with potential clinical utility, we enriched and profiled the glycoprotein component of urine samples by using a dual-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry platform. Results: From a primary sample set obtained from 54 cancer patients and 46 controls, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was done on an independent set of 70 samples (35 cancer cases) by using an ELISA. Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74{\%} and specificity of 80{\%}. Summary: The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer.",
author = "Na Yang and Shun Feng and Kerby Shedden and Xiaolei Xie and Yashu Liu and Rosser, {Charles J.} and Lubman, {David M.} and Steven Goodison",
year = "2011",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-10-3121",
language = "English (US)",
volume = "17",
pages = "3349--3359",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification

AU - Yang, Na

AU - Feng, Shun

AU - Shedden, Kerby

AU - Xie, Xiaolei

AU - Liu, Yashu

AU - Rosser, Charles J.

AU - Lubman, David M.

AU - Goodison, Steven

PY - 2011/5/15

Y1 - 2011/5/15

N2 - Background: Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the United States. Early clinical diagnosis of bladder cancer remains a major challenge, and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. Approach: To identify urinary proteins with potential clinical utility, we enriched and profiled the glycoprotein component of urine samples by using a dual-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry platform. Results: From a primary sample set obtained from 54 cancer patients and 46 controls, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was done on an independent set of 70 samples (35 cancer cases) by using an ELISA. Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. Summary: The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer.

AB - Background: Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the United States. Early clinical diagnosis of bladder cancer remains a major challenge, and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. Approach: To identify urinary proteins with potential clinical utility, we enriched and profiled the glycoprotein component of urine samples by using a dual-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry platform. Results: From a primary sample set obtained from 54 cancer patients and 46 controls, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was done on an independent set of 70 samples (35 cancer cases) by using an ELISA. Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. Summary: The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=79956044485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956044485&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-3121

DO - 10.1158/1078-0432.CCR-10-3121

M3 - Article

C2 - 21459797

AN - SCOPUS:79956044485

VL - 17

SP - 3349

EP - 3359

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -